News
NYC public hospitals rose to the demands of the COVID-19 crisis
August 31, 2020
“We hospitalists, and all those recruited to act as hospitalists, essentially took responsibility for the COVID response.”
News
DAPA-CKD: SGLT2 inhibitor benefit extends to chronic kidney disease without diabetes
August 31, 2020
DAPA-CKD showed that dapagliflozin helps patients with albuminuria and declining eGFR levels whether or not they have type 2 diabetes.
News
COVID-19 at home: What does optimal care look like?
August 31, 2020
Most attention has focused on the sickest patients, leaving less severe cases to fall through the cracks.
News
EMPEROR-Reduced: Empagliflozin’s HFrEF benefit solidifies class effects
August 30, 2020
The 25% cut in primary endpoints among HFrEF patients on empagliflozin matched the benefit seen before from dapagliflozin in DAPA-HF.
News
Early rhythm control in AFib gains new life
August 30, 2020
EAST-AFNET 4 trial reanimates rhythm-control strategy as superior for 5-year cardiovascular outcomes.
News
SARS-CoV-2 appears unlikely to pass through breast milk
August 28, 2020
Researchers detected viral RNA in a breast milk sample from one woman with COVID-19 disease, but culture was negative.
News
FDA approves point-of-care COVID-19 antigen test
August 27, 2020
“This new COVID-19 antigen test is an important addition to available tests because the results can be read in minutes, right off the testing card.”
News
COVID-19 vaccine supply will be limited at first, ACIP says
August 27, 2020
The working group expects that from 15 to 45 million doses of vaccine will be available by the end of December, depending on which vaccine is approved by then or whether both are approved.
News
Asymptomatic SARS-CoV-2 infections in kids tied to local rates
August 27, 2020
It is unclear how many children remain asymptomatic in comparison with those who were in a presymptomatic phase at the time of testing.
News
Convalescent plasma actions spark trial recruitment concerns
August 26, 2020
“It’s not clear that people with COVID-19, especially those who are severely ill and hospitalized, will choose to enlist in a clinical trial – where they could receive a placebo – when they instead could get plasma.”